Want to see ALNY full AI Analyst Report?
ALNY Stock Chart & Stats
$309.66
-$0.58(-0.25%)
At close: 4:00 PM EST
$309.66
-$0.58(-0.25%)
Day’s Range― - ―
52-Week Range$266.43 - $495.55
Previous CloseN/A
Volume78.96K
Average Volume (3M)1.45M
Market Cap
$35.71B
Enterprise Value$45.70K
Total Cash (Recent Filing)$3.01B
Total Debt (Recent Filing)$1.27B
Price to Earnings (P/E)61.3
Beta0.92
Next Earnings
Jul 30, 2026EPS Estimate
1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.36
Shares Outstanding133,512,570
10 Day Avg. Volume1,904,847
30 Day Avg. Volume1,453,347
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)66.01
Price to Sales (P/S)14.03
P/FCF Ratio111.94
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$458.29Price Target Upside48.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)7.45
Revenue Forecast (FY)$5.58B
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationAlnylam has moved from negative cash flow to sustained free cash generation (TTM OCF ~$713M; FCF ~$641M). Durable cash flow supports funding launches, late‑stage trials and strategic deals without immediate capital raises, reducing financing risk over the next 2–6 months.
Leading TTR Commercial FranchiseThe TTR franchise delivered substantial, repeatable revenue (Q1 TTR $910M; record quarter >$1B product sales), driven by prescriber expansion, high adherence and international launches. This durable commercial execution underpins predictable cashflows and scales margins as uptake continues.
Strategic R&D And Data PartnershipsThe Inceptive deal (up to $2B) and expanded analytics/commercial partnerships institutionalize AI-driven discovery and real-world analytics. These structural investments accelerate pipeline expansion and target discovery throughput aligned with Alnylam 2030 goals, strengthening long-term R&D productivity.
Bears Say
Rising Royalty PressureAverage royalties on AMVUTTRA are set to increase as sales ramp, already contributing to a 5‑percentage‑point gross margin decline. This structural royalty reset will compress product gross margins and long‑term operating leverage unless mitigated by price, mix or lower costs.
Heavy Reinvestment BurdenSizable year‑over‑year increases in R&D and SG&A reflect multi‑Phase III programs and launch investments. While strategic for growth, sustained high operating spend elevates breakeven needs and operating‑leverage risk if top‑line momentum slows, pressuring margins over coming quarters.
Moderate Leverage And Prior Thin EquityLeverage remains moderate (debt ~$1.27B; TTM D/E ~1.18) and the company has a history of very thin/negative equity. This makes capital structure sensitive to profit reversals and could constrain strategic flexibility or raise financing costs if cash generation weakens.
Alnylam Pharma News
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $266.43 and its highest was $495.55 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $35.71B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Apr 30, 2026. The company reported $1.51 earnings per share for the quarter, beating the consensus estimate of $0.872 by $0.638.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 1.61.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 133,512,570 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of $1.51 in its last earnings report, beating expectations of $0.872. Following the earnings report the stock price went up 2.756%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in ALNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alnylam Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$458.29 (48.00% Upside)
$458.29 (48.00% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 263.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 16.9%
Last 30 Days ▲ 16.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.62%
12-Months-Change
Fundamentals
Return on Equity
98.29%
Trailing 12-Months
Asset Growth
21.73%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
ALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
ALNY Stock 12 Month Forecast
Average Price Target
$458.29
▲(48.00% Upside)
Technical Analysis
Ownership Overview
0.26% Insiders
45.11% Mutual Funds
0.44% Other Institutional Investors
31.71% Public Companies and Individual Investors